Inhalon
Karissa Marino currently serves as a Scientist at Inhalon Biopharma since June 2023, following a position as Research Associate II at Cell Microsystems from December 2022 to June 2023. Previous roles include Scientist at Mucommune from September 2020 to November 2022 and Research Associate in In Vitro Assay Development at ScitoVation from July 2019 to September 2020, where ScitoVation provided safety assessments of chemical compounds. Karissa's academic background includes a Bachelor's degree in Biology from the University of North Carolina at Chapel Hill, earned between 2017 and 2019, and an Associate of Science degree from Alamance Community College from 2015 to 2017. Additionally, Karissa worked as a Research Assistant in the Department of Microbiology and Immunology at the University of North Carolina at Chapel Hill from August 2018 to May 2019.
Inhalon
Inhalon Biopharma is developing an inhaled immunotherapy platform for treating acute respiratory infections (ARI), such as syncytial virus (RSV), influenza, metapneumovirus (MPV), parainfluenza virus (PIV), adenovirus, severe acute respiratory syndrome (SARS) and middle east respiratory syndrome (MERS). Today there are no approved treatments for a wide range of ARIs that can lead to hospitalization, long-term health complications, and sometimes death.